Janssen Reminyl Benefit Seen Among Probable Vascular Dementia Patients
Executive Summary
A study of Janssen's Reminyl (galantamine) showed benefits in patients with probable vascular dementia as well as patients with Alzheimer's disease with cerebrovascular components.
You may also be interested in...
Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
Vascular dementia may not be a distinct clinical entity that could be indicated in drug labeling, FDA's Peripheral & Central Nervous System Drugs Advisory Committee suggested.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011